Yahoo Web Search

Search results

1. • 

     Immunosuppression Risk Factor for Poor cSCC Outcomes

     Medscape· 5 days ago

     In contrast to earlier findings, immunosuppression was an independent risk factor for disease-specific death and major poor outcomes.

2. • INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights

     WTNH-TV New Haven· 1 day ago

     Of utmost importance, we remain on track to submit our BLA in the second half of 2024 under the accelerated approval pathway for INO-3107 as a treatment for RRP and are working ...

3. • Plasma proteome profiling reveals dynamic of cholesterol marker after dual blocker therapy - Nature...

     Nature· 7 days ago

     Dual blockade therapy is currently being trialled for multiple tumour types, but efficacy is variable. Here, the authors use longitudinal proteomics profiling of 22 patients to develop a predictive model of therapy response.

4. • DNA Medicine Focused INOVIO Pharma Efficiencies Implemented By Leadership Will Help De-Risk Its...

     Benzinga· 8 hours ago

     The analyst writes that the FDA considered lead program INO-3107 Phase 1/2 clinical trials sufficient for the Accelerated Approval Program. If approved, INO-3107 could be the first non-surgical ...

5. • Wedbush Boosts Janux Therapeutics (NASDAQ:JANX) Price Target to $74.00

     ETF DAILY NEWS· 4 days ago

     Janux Therapeutics (NASDAQ:JANX – Free Report) had its target price increased by Wedbush from $53.00 to $74.00 in a research note published on Wednesday morning, Marketbeat reports. The brokerage ...

6. • 

     Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Cevira...

     WROC Rochester· 3 days ago

     Cevira (APL-1702) is a photodynamic drug-device combination product in development for the...

7. • Leerink Partnrs Weighs in on InflaRx’s FY2024 Earnings (NASDAQ:IFRX)

     ETF DAILY NEWS· 2 days ago

     InflaRx (NASDAQ:IFRX – Free Report) – Analysts at Leerink Partnrs boosted their FY2024 earnings per share estimates for InflaRx in a research report issued on Wednesday, May 8th. Leerink Partnrs ...

8. • Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting

     WPRI Providence· 2 days ago

     The volume of data being presented by Astellas reinforces its commitment to changing the course of cancer treatment through targeted therapies for hard-to-treat cancers like ...

9. • Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination...

     Benzinga· 21 hours ago

     OSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that

10. • Adlai Nortye Ltd. (NASDAQ:ANL) Short Interest Update

      ETF DAILY NEWS· 3 days ago

      Adlai Nortye Ltd. (NASDAQ:ANL – Get Free Report) saw a large growth in short interest in the month of April. As of April 30th, there was short interest totalling 11,500 shares, a growth of 101.8% ...